Andrew Berens has given his Buy rating due to a combination of factors, primarily centered around Nuvalent’s promising developments in their ALK and ROS1 programs. The company has shown significant ...
During a Case-Based Roundtable® event, Chul Kim, MD, discussed the ALTA-1 trial and BRIGHTSTAR trials of brigatinib in ALK+ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback